Early success of COVID-19 vaccine candidates fuels optimism, but experts warn 'a lot has to go right'

  • USA Today | by: Elizabeth Weise and Karen Weintraub |
  • 07/23/2020 12:00 AM
Early success of COVID-19 vaccine candidates fuels optimism, but experts warn 'a lot has to go right'
Photo Credit: Javier Zarracina/USA Today

To win approval, a vaccine must be at least 50% more effective than a placebo in preventing or decreasing the severity of COVID-19.

There had been concern the FDA might face pressure from the White House to lower its standards and approve a COVID-19 vaccine before the Phase 3 trials are done. President Donald Trump has repeatedly promised an approved vaccine by late this year. 

The FDA's actions around a drug called hydroxychloroquine – which it approved under emergency use, then rescinded approval – raised questions about the agency's independence from the Trump administration. The president strongly supported the drug based on weak early data that has been largely contradicted. 

The strong COVID-19 vaccine guidance put some of those concerns to rest, said Peter Pitts, president of the Center for Medicine in the Public Interest. The agency set clear parameters for what "good science" looks like, with solid safety and large effectiveness trials.

“The FDA is saying that it’s not going to be rubber-stamping any vaccines for COVID-19,” he said.

The agency explained how the testing process can be safely streamlined, Nagarkatti said.

“The FDA’s guidance document and Emergency Use Authorization is not trying to cut short safety but to eliminate steps that are time-consuming while sticking to the principle that the benefits should outweigh the risks. This is always the goal of the vaccine,” he said.
 
Sign Up for Our Email Newsletter

RECENT NEWS

Concerns Arise Over Protests During Coronavirus Pandemic

Concerns Arise Over Protests During Coronavirus Pandemic

Peter Pitts appears on NBC 6 Miami with Sheli Muñiz to discuss the protests and spread of coronavirus...  Read more

$40 price tag for potential coronavirus vaccine seems to be ‘right on the money,’ says think tank

$40 price tag for potential coronavirus vaccine seems to be ‘right on the money,’ says think tank

If a potential coronavirus vaccine is not affordable, too many people will not get vaccinated, says Peter Pitts, presiden...  Read more

U.S. sets global benchmark for COVID-19 vaccine price at around the cost of a flu shot

U.S. sets global benchmark for COVID-19 vaccine price at around the cost of a flu shot

The U.S. government has set a benchmark for COVID-19 vaccine pricing in a $2 billion deal announced on Wednesday with Pfi...  Read more

DRUGWONKS BLOG